Charles River Labs Intl

CRL-N

NYSE:CRL

228.97
2.52 (1.11%)
Charles River Laboratories, Inc., is an American corporation specializing in a variety of pre-clinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries.
More at Wikipedia

Analysis and Opinions about CRL-N

Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
June 17, 2020
(A Top Pick May 30/19, Up 44%) A contract research organization who partners with major pharma companies for drug testing and clinical testing. This is the second company in this space that has done well for them. He would stick with it.
Show full opinionHide full opinion
(A Top Pick May 30/19, Up 44%) A contract research organization who partners with major pharma companies for drug testing and clinical testing. This is the second company in this space that has done well for them. He would stick with it.
WAIT
WAIT
July 10, 2019
It has had a great run and they consistently beat earnings expectations. He would be modestly concerned about their value metrics -- you are paying up right now. It has a 40 times PE ratio. He would wait until earnings are released.
Show full opinionHide full opinion
It has had a great run and they consistently beat earnings expectations. He would be modestly concerned about their value metrics -- you are paying up right now. It has a 40 times PE ratio. He would wait until earnings are released.
TOP PICK
TOP PICK
May 30, 2019
They are a contractor to pharma labs. A lot of large pharma companies outsource to them. They have predictable margins. They are growing organically and through acquisition. (Analysts’ price target is $148.13)
Show full opinionHide full opinion
They are a contractor to pharma labs. A lot of large pharma companies outsource to them. They have predictable margins. They are growing organically and through acquisition. (Analysts’ price target is $148.13)
TOP PICK
TOP PICK
May 3, 2016

Does safety testing, the efficacy, phase 1 through 3 trials for particular drugs for pharmaceutical companies. High growth, growing earnings last year at 17%.

Show full opinionHide full opinion

Does safety testing, the efficacy, phase 1 through 3 trials for particular drugs for pharmaceutical companies. High growth, growing earnings last year at 17%.

Showing 1 to 4 of 4 entries
  • «
  • 1
  • »

Charles River Labs Intl(CRL-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 1

Stockchase rating for Charles River Labs Intl is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Charles River Labs Intl(CRL-N) Frequently Asked Questions

What is Charles River Labs Intl stock symbol?

Charles River Labs Intl is a American stock, trading under the symbol CRL-N on the New York Stock Exchange (CRL). It is usually referred to as NYSE:CRL or CRL-N

Is Charles River Labs Intl a buy or a sell?

In the last year, 1 stock analyst published opinions about CRL-N. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is PAST TOP PICK. Read the latest stock experts' ratings for Charles River Labs Intl.

Is Charles River Labs Intl a good investment or a top pick?

Charles River Labs Intl was recommended as a Top Pick by Gordon Reid on 2020-06-17. Read the latest stock experts ratings for Charles River Labs Intl.

Why is Charles River Labs Intl stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Charles River Labs Intl worth watching?

1 stock analyst on Stockchase covered Charles River Labs Intl In the last year. It is a trending stock that is worth watching.

What is Charles River Labs Intl stock price?

On 2020-10-01, Charles River Labs Intl (CRL-N) stock closed at a price of $228.965.